ZA202406375B - Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof - Google Patents

Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof

Info

Publication number
ZA202406375B
ZA202406375B ZA2024/06375A ZA202406375A ZA202406375B ZA 202406375 B ZA202406375 B ZA 202406375B ZA 2024/06375 A ZA2024/06375 A ZA 2024/06375A ZA 202406375 A ZA202406375 A ZA 202406375A ZA 202406375 B ZA202406375 B ZA 202406375B
Authority
ZA
South Africa
Prior art keywords
quinolines
pyrazolo
substituted
preparation
methods
Prior art date
Application number
ZA2024/06375A
Other languages
English (en)
Inventor
Ruben Abagyan
Oleg Mitkin
Vladislav Zenonovich Parchinsky
Alexei Pushechnikov
Alexandre Vasilievich Ivachtchenko
Nikolay Savchuk
Original Assignee
Lomond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lomond Therapeutics Inc filed Critical Lomond Therapeutics Inc
Publication of ZA202406375B publication Critical patent/ZA202406375B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2024/06375A 2021-10-15 2024-08-20 Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof ZA202406375B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163256260P 2021-10-15 2021-10-15

Publications (1)

Publication Number Publication Date
ZA202406375B true ZA202406375B (en) 2025-01-29

Family

ID=85988576

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/06375A ZA202406375B (en) 2021-10-15 2024-08-20 Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof

Country Status (11)

Country Link
US (1) US20250011319A1 (enExample)
EP (1) EP4416146A4 (enExample)
JP (1) JP2024539633A (enExample)
KR (1) KR20240093606A (enExample)
CN (1) CN118076605A (enExample)
AU (1) AU2022364646B2 (enExample)
CA (1) CA3233233A1 (enExample)
MX (1) MX2024004569A (enExample)
TW (2) TWI863003B (enExample)
WO (1) WO2023064133A1 (enExample)
ZA (1) ZA202406375B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
MA42456B1 (fr) * 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US12486264B2 (en) * 2019-03-26 2025-12-02 Janssen Pharmaceutica Nv Bicyclic HPK1 inhibitors
US20210269434A1 (en) * 2020-01-10 2021-09-02 Incyte Corporation Tricyclic compounds as inhibitors of kras
AU2021254794A1 (en) * 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors

Also Published As

Publication number Publication date
AU2022364646B2 (en) 2025-10-09
EP4416146A1 (en) 2024-08-21
CA3233233A1 (en) 2023-04-20
AU2022364646A1 (en) 2024-03-28
CN118076605A (zh) 2024-05-24
JP2024539633A (ja) 2024-10-29
TW202317567A (zh) 2023-05-01
TWI863003B (zh) 2024-11-21
TW202442645A (zh) 2024-11-01
MX2024004569A (es) 2024-04-30
US20250011319A1 (en) 2025-01-09
WO2023064133A1 (en) 2023-04-20
EP4416146A4 (en) 2025-11-05
KR20240093606A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
WO2022216971A9 (en) Pyridazine compounds for inhibiting nlrp3
MX2023009086A (es) Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos.
MX2022013417A (es) Inhibidores de fosfatidilinositol 3 cinasa (pi3k) alfa y metodos de uso de los mismos.
ZA202406375B (en) Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
AP2004003100A0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
ATE331514T1 (de) Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
HRP20050967B1 (hr) Derivati pirazolo-kinazolina, postupak njihovog dobivanja i njihova uporaba kao inhibitora kinaze
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
DE60212627D1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
WO2003024386A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.
IL175875A0 (en) Substituted 1h-pyrrolo[3,2-b, 3,2-c and 2,3-c] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
MX2024013762A (es) Inhibidores de fosfatidilinositol 3-cinasa alfa (pi3kalfa) y metodos de uso de los mismos
MX2024013843A (es) Compuestos dirigidos a bmr y métodos de uso asociados
MX2025002705A (es) Isoquinolonas como inhibidores de pi3k
DE60307237D1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
ATE343415T1 (de) Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
MX2025011886A (es) Derivados biciclicos semisaturados y usos relacionados
ATE401078T1 (de) Die verwendung von c-kithemmern zur förderung des haarwuchses
MX2023010083A (es) Derivados heterociclicos como inhibidores de cinasas jano.
HK20075235A1 (en) Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
HK20113541A1 (zh) 经取代的1h-吡唑并[4，3-c]喹啉、其制备方法及用途
JOP20250005A1 (ar) مثبطات التيروسين كيناز 2 واستخداماتها
MX2024008270A (es) Inhibidores del linfoma 2 de celulas b.
HK20067397A1 (en) Compounds having 1h-pyrazolo[4,3-c]pyridin-6-amino as therapeutic agents